

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

Hsd:Athymic Nude-Foxn1^{nu}

RRID:IMSR_ENV:HSD-069

Type: Organism

Proper Citation

RRID:IMSR_ENV:HSD-069

Organism Information

URL: <https://www.envigo.com/model/hsd-athymic-nude-foxn1nu>

Proper Citation: RRID:IMSR_ENV:HSD-069

Description: Mus musculus with name Hsd:Athymic Nude-Foxn1^{nu} from IMSR.

Species: Mus musculus

Notes: gene symbol note: forkhead box N1; outbred stock|mutant stock: Foxn1

Affected Gene: forkhead box N1

Genomic Alteration: nude

Catalog Number: ENV:HSD-069

Database: Envigo an Inotiv Company

Database Abbreviation: ENV

Availability: live

Organism Name: Hsd:Athymic Nude-Foxn1^{nu}

Record Creation Time: 20250513T061850+0000

Record Last Update: 20260801T055441+0000

Ratings and Alerts

No rating or validation information has been found for Hsd:Athymic Nude-Foxn1^{nu}.

No alerts have been found for Hsd:Athymic Nude-Foxn1^{nu}.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Envigo an Inotiv Company

Usage and Citation Metrics

We found 113 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Manabe T, et al. (2026) Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies. Nature communications, 17(1).

Seijo-Vila M, et al. (2026) Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response. Oncogene, 45(25), 2436.

Murillo D, et al. (2026) Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma. Drug delivery, 33(1), 2671485.

Kelley VM, et al. (2026) Loss of JAK1 Function Causes G2-M Cell-Cycle Defects Vulnerable to KIF18A Inhibition. Cancer research, 86(9), 2301.

Tankka AT, et al. (2026) Integrative CRISPR Screening and RNA Analyses Discover an Essential Role for PUF60 Interactions with 3' Splice Sites in Cancer Progression. Cancer research, 86(7), 1586.

Cando LF, et al. (2026) Targeting microRNA let-7b-5p-mediated aberrant androgen receptor signaling for prevention of hormone receptor-negative breast cancer. NPJ breast cancer.

Roger E, et al. (2026) ATM Deficiency Induces TGF β -Mediated Stromal Programming in Pancreatic Cancer. Cancer research, 86(14), 3412.

Zhao Z, et al. (2026) NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis. Cancer letters, 655, 218636.

Zangari J, et al. (2025) D-cysteine impairs tumour growth by inhibiting cysteine desulfurase NFS1. Nature metabolism, 7(8), 1646.

Kalva SK, et al. (2025) LED-based optoacoustic tomography of mice. Journal of biomedical optics, 30(4), 040501.

de Goñi I, et al. (2025) Generation and Characterization of Novel Contilisan+Tubastatin a Multitarget Small Molecules Against Glioblastoma. Pharmaceuticals, 17(12).

Artetxe-Zurutuza A, et al. (2025) Generation and validation of a novel multitarget small molecule in glioblastoma. Cell death & disease, 16(1), 250.

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 1069.

Artetxe-Zurutuza A, et al. (2025) Characterization of a Novel Family of Contilisant + Belinostat Multitarget Small Molecules in Glioblastoma. *Pharmaceuticals (Basel, Switzerland)*, 19(1).

Manabe T, et al. (2025) Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies. *Research square*.

Kesh K, et al. (2025) Targeting Triple-Negative Breast Cancer with Momordicine-I for Therapeutic Gain in Preclinical Models. *Cancers*, 17(14).

Domínguez-Vigil IG, et al. (2025) PLK4 Inhibition as a Strategy to Enhance Non-Small Cell Lung Cancer Radiosensitivity. *Molecular cancer therapeutics*, 24(9), 1350.

Feng Y, et al. (2025) Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(16), 3537.

Kenny HA, et al. (2025) Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. *Molecular cancer therapeutics*, 24(8), 1252.

Lindland K, et al. (2025) Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. *Molecular cancer therapeutics*, 24(9), 1415.